Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT06128564

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

Conditions: Duchenne Muscular Dystrophy

Sex: Male

Ages: 2 Years – 3 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 13

Sponsor: Hoffmann-La Roche

Location: Chr de La Citadelle Liège

Summary

This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.

Eligibility Criteria

Inclusion Criteria: * Cohort A: \>=3 years of age to \=2 years of age to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06128564). StuddyBuddy aggregates publicly available trial information.